RIPOR3

Across TCGA pan-cancer cohorts, RIPOR3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RIPOR3 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RIPOR3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RIPOR3 expression acts as an unfavorable survival marker.

LUSC, MESO, and UCEC are the cancer types where RIPOR3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RIPOR3–LUSC (OS)

Open the LUSC breakdown →